Sold as Gomekli. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Mirdametinib (sold as Gomekli), first approved Feb 11, 2025, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Gomekli | Part D | $12.7M | New | 98 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young AdultsLGCMN, Large and Giant Congenital Melanocytic Nevi · National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Oct 23, 2026 |
| A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasNeurofibromatosis Type 1-Associated Plexiform Neurofibromas · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Phase 1 | Not yet recruiting | Sep 30, 2026 |
| A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsHealthy · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 | Recruiting | Sep 25, 2026 |
| A Study of Mirdametinib in People With Central Nervous System TumorsCentral Nervous System Tumors, Glioma · Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 | Recruiting | Apr 20, 2026 |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaNeurofibromatosis 1 (NF1) · University of Alabama at Birmingham | Phase 2 | Not yet recruiting | Apr 13, 2026 |
| Mirdametinib in Patients With Advanced NF1-mutant MelanomaAdvanced Unresectable Melanoma, Metastatic Melanoma · Kevin Kim, MD | Phase 2 | Recruiting | Nov 19, 2025 |
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma · National Cancer Institute (NCI) | Phase 2 | Recruiting | Jul 14, 2025 |
| Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibHealthy, Hepatic Impairment · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Phase 1 | Recruiting | May 30, 2025 |
| Feb 11, 2025 | GomekliNDA 219379 · New molecular entity | Springworks | 0 | Marketed |
| Feb 11, 2025 | GomekliNDA 219389 · New dosage form | Springworks | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA